Zidolam N 300mg Tablet (Lamivudine (150mg) + Zidovudine (300mg) + Nevirapine (200mg))

Zidolam N 300mg Tablet Tenolam Tablet is prescribed to treat HIV (human immunodeficiency virus) infection. It is the combination of three antiretrovirals medicines such as Lamivudine (150mg), Zidovudine (300mg), and Nevirapine (200mg). Zidolam prevent the multiplication of HIV and reduces the viral load in the body by blocking the specific pathways responsible for the virus multiplication. It also increases the CD4 cell count in the blood. Moreover, this tablet boosts immune functioning to fight against HIV infection and manage or treat AIDS. Always take it under medical supervision.

HIV

It is a strong anti-HIV medicine that may show certain adverse while manageable impact on the body during the treatment. As these effects resolve on their own without any special medical attention. However, if you ever experience serious or unusual side effects contact your healthcare professional immediately.
Some common side effects include:
● Rash
● Headache
● Abdominal pain
● Muscle pain

Doctor determines the dosage and duration of Zidolam N 300mg Tablet(Lamivudine 150mg, Zidovudine 300mg, and Nevirapine 200mg) as per the severity of the infection as well as age & overall health condition of the patients. Swallow it as a whole with water and don't chew, crush or break the tablet. This tablet may be taken with or without food. In case of an overdose of this tablet, contact your doctor or any healthcare provider and seek medical attention immediately.

● Ungsedhapand, C., Kroon, E. D., Suwanagool, S., Ruxrungtham, K., Yimsuan, N., Sonjai, A., ... & Phanuphak, P. (2001). A randomized, open-label, comparative trial of zidovudine plus lamivudine versus zidovudine plus lamivudine plus didanosine in antiretroviral-naive HIV-1-infected Thai patients. JAIDS Journal of Acquired Immune Deficiency Syndromes, 27(2), 116-123.
● Perry, C. M., & Faulds, D. (1997). Lamivudine: a review of its antiviral activity, pharmacokinetic properties and therapeutic efficacy in the management of HIV infection. Drugs, 53(4), 657-680.
● Bartlett, J. A., Benoit, S. L., Johnson, V. A., Quinn, J. B., Sepulveda, G. E., Ehmann, W. C., ... & North American HIV Working Party*. (1996). Lamivudine plus zidovudine compared with zalcitabine plus zidovudine in patients with HIV infection: a randomized, double-blind, placebo-controlled trial. Annals of internal medicine, 125(3), 161-172.
● Anderson, P. L., & Rower, J. E. (2010). Zidovudine and lamivudine for HIV infection. Clinical medicine reviews in therapeutics, 2, a2004.
● Podzamczer, D., Ferrer, E., Consiglio, E., Gatell, J. M., Perez, P., Perez, J. L., ... & Combine Study Team (members listed in Appendix). (2002). A randomized clinical trial comparing nelfinavir or nevirapine associated to zidovudine/lamivudine in HIV-infected naive patients (the Combine Study). Antiviral therapy, 7(2), 81-90.